Released Feb 26, 2024, after the close
10-K filed Feb 26, 2024, 57 days after period end · 0000950170-24-020158
Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.68M$1.68M derived−96.2% vs Q4 2022−13.8% vs Q3 2023
Net Income-$44.12M-$44.12M derivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$48,075,000N/M
Operating Cash Flowderived-$36,637,000N/M
Free Cash Flowderived-$36,818,000N/M
Margins · derived
Operating margin-2868.4%−2723.2 pt vs Q4 2022
Net margin-2632.6%−2505.5 pt vs Q4 2022
What the release said
The release
Same quarter
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | $1.68M | $44.36M | $17.07M | $15.90M |
| Net Income | -$44.12M | -$56.36M | -$68.62M | -$53.11M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR